The Latest Breaking News from Biogen Inc

Biotech stocks are surging as groundbreaking neuroscience and gene therapy innovations take center stage. Amid this backdrop, investors might consider adding fundamentally strong biotech stocks like Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Gilead Sciences (GILD) to their portfolio for an impactful investment. Continue reading….

The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To capitalize on the industry’s expansion, it could be wise to invest in fundamentally sound biotech stocks, Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), and Biogen (BIIB), which have the potential to revolutionize medicine. Read…

Despite macroeconomic challenges, the biotech industry thrives on innovation, demand, adaptability, and technological advancements, demonstrating resilience. So, let’s analyze the upside potential of popular biotech stocks Biogen (BIIB) and Moderna (MRNA).

Because of its strategic focus on research and therapy improvements for long-term growth, Biogen (BIIB) could come under heat for the mixed outcomes of its recent acquisitions. As stakeholders anticipate the forthcoming earnings release, let's seek insights into the company's future trajectory and implications for BIIB shares. Read on….

Amid the use of advanced technologies, personalized medicines, demand for quality treatments and therapies, and an aging population, the biotech industry appears to be on a steady path for expansion. Given this backdrop, let’s analyze the fundamentals of Biogen (BIIB), BioNTech (BNTX), and Kura (KURA) to determine which of these…

Rising healthcare needs, significant investments in R&D, robust drug pipeline, and use of advanced technology are some factors driving the biotech industry’s growth. Amid this favorable backdrop, let’s evaluate Gilead (GILD), Biogen (BIIB) and Karuna Therapeutics (KRTX) to determine the best investment action. Read more.

Biotech major Biogen (BIIB) will report its third-quarter results on November 8. Its EPS and revenue are expected to decline year-over-year. However, the FDA approvals for new drugs received by the company this year will likely support its long-term growth. Let’s discuss the potential road ahead for the stock….

Robust demand, technological advancements, government and private investment, are fueling the biotech industry’s expansion and driving game-changing therapies and product development. With the industry anticipated to thrive, fundamentally strong biotech stocks Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and United Therapeutics (UTHR) look poised for substantial gains. Keep reading.

Biotech companies such as Biogen (BIIB), Cidara Therapeutics (CDTX), and Theratechnologies (THTX) with the interest of institutional investors could be worth investing in now. Continue reading….